The conversion of naive T cells into Treg can be achieved in vivo by delivery of antigen under subimmunogenic conditions. Here we have examined several drugs for their ability to enhance the conversion process in vivo and have found that the rapamycin analog everolimus potently enhances Treg conversion by interfering with T-cell costimulation, reducing cell division and thereby activation of DNA methyltransferase 1 as well as by reducing T-cell activation through the ATP-gated P2×7 receptor controlling Ca2 + influx. The resulting Tregs exhibit increased stability of Foxp3 expression even when generated in TGFβ-containing media in vitro. Thus the mammalian target of rapamycin (mTOR) inhibitor everolimus in addition to inhibiting immune responses enhances Treg conversion by several distinct pathways. The converted Tregs can be further expanded by injection of IL-2/IL-2ab complexes. These complexes also increase the number of CD25 +
Foxp3
− cells that, however, do not represent cytokine secreting effector cells but anergic cells, some of which can secrete IL-10 and can themselves be considered regulatory T cells as well. The combined use of everolimus and IL-2/IL-2ab complexes in vivo makes it feasible to achieve highly effective antigen-driven conversion of naive T cells into Treg and their expansion in vivo and thereby the described protocols constitute important tools to achieve immunological tolerance by Treg vaccination.
antigen-specific Treg conversion | Foxp3 | IL-2/IL-2ab complexes | mammalian target of rapamycin | prospective tolerance A t present it is unclear how much the conversion of naive T cells into Treg in peripheral lymphoid tissue contributes to the control of immunity by Treg. On the other hand, it seems reasonable to exploit this conversion process to control unwanted immune responses. In the past our lab has described several strategies to induce such conversion by exogenous antigens with the aim to study whether Treg conversion can be used to induce tolerance to antigens, including transplantation antigens, prospectively (1-3). We were successful in using this approach to induce prospective tolerance in female mice to a variety of male tissues, including skin and hematopoetic grafts (4) .
With regard to mechanisms it became clear that Treg conversion in vivo is best achieved by subimmunogenic delivery of strong agonists under conditions that avoid functional activation of antigen presenting cells (5) (6) (7) (8) (9) . Also, in accordance with more recent data (10) , in this setting, best conversion is seen in T cells that undergo only limited proliferation, whereas higher doses of the strong agonist result in more extensive proliferation and diminished conversion (5) . Thus these studies that addressed Treg conversion by monitoring the generation of Foxp3-expressing Treg in vivo confirmed anecdotal evidence of generating "dominant" tolerance by subimmunogenic antigen delivery (10) .
Comparison of such converted Treg with Treg generated by T-cell stimulation in vitro in the presence of relatively high doses of transforming growth factor beta TGFβ (12) showed that in vitrogenerated Treg exhibited marked differences: the in vitro conversion process was much faster and resulted in Treg with unstable Foxp3 expression that correlated with lack of demethylation of the Foxp3 locus, whereas the in vivo method resulted in complete demethylation and stable Foxp3 expression (13) . In fact in some aspects the in vivo protocol was more akin to a different in vitro conversion method where T-cell activation was limited for an initial 18-h culture period in the absence of exogenously added TGFβ and activation of the PI3 kinase pathway was limited (14) .
Because stability of Foxp3 expression appeared mandatory for the induction of prospective tolerance, we thought to make the in vivo conversion more efficient with drugs that would either enhance the conversion process or expand already converted cells because previous analyses had shown that converted cells could be easily expanded in vivo even under conditions when antigens were delivered in an immunogenic context (2, 3, 5) . The results show that in vivo Treg conversion can be markedly enhanced by drugs that interfere with signals generated through the phosphatidyl inositol 3 kinase (PI3K) pathway and that converted Treg can be expanded by drugs that induce strong proliferation. With regard to expansion of Treg by IL-2/IL-2 ab complexes, we focused our attention on the properties of CD25 +
− cells that could represent activated, cytokine-producing effector cells. The results, however, show that these cells resemble regulatory T cells in that they are anergic and secrete either no or only suppressive cytokines.
Results and Discussion
Enhancing Treg Conversion in Vivo. Because costimulation is counterproductive to Treg conversion in vivo (5) and because in vitro results showed that interference with the PI3K pathway, especially inhibition of the mammalian target of rapamycin (mTOR), could affect Treg conversion (14-16), we delivered antigen either by osmotic minipumps or DEC205 fusion antibodies in combination with or without the rapamycin analog everolimus, which inhibits mTOR. Everolimus was given for 14 d either together with the peptide when peptide was delivered by osmotic minipumps or after antigen was delivered at day 1 in the form of 40 ng of DEC205 fusion antibody. As a readout, two T-cell receptor (TCR) transgenic systems coupled with a Foxp3 reporter (17) were used; i.e., either female Marilyn mice (18) that express TCR transgenes encoding a receptor specific for HY peptide presented by I-A b MHC complexes and also expressed a Foxp3 reporter knockin. Alternatively, we used naive T cells expressing an HA-specific TCR (19) and the Foxp3 reporter, which were transferred into congenic unmanipulated BALB/c mice before injection with 40 ng of DEC205 antibody fused with the HA peptide.
As shown in Fig. 1 i.p. application of everolimus (at a dose of 100 μg/mouse/d = 5 mg/kg) markedly increased the Treg-conversion rate such that a much higher proportion of T cells in both experimental systems expressed Foxp3. Representative data of Foxp3 expressing Tregs from spleens are shown ( Fig. 1 A and B a high proportion of Tregs even at later stages after application, whereas absolute numbers declined due to a general decline in transferred cells (Fig. 1C Lower) . The combination of antigen plus everolimus injection followed by injection of IL-2/IL-2 antibody complexes clearly represented the most powerful means of increasing Treg numbers, but as earlier demonstrated (20) , the expanded proportion and absolute number of Tregs were not stable over prolonged time periods. Thus in contrast to the conversion enhanced by everolimus, which resulted in a nearly stable high proportion of converted Tregs up to several weeks after conversion (Fig. 1C) , the expansion of Treg is transient. The deficit in Tregs observed several weeks after expansion with IL-2/IL-2 antibody complexes could be ameliorated by renewed injection of these compounds (Fig. 1D) .
In further in vivo as well as in vitro experiments, we analyzed possible pathways by which everolimus enhanced Treg conversion to establish whether combinations of different drugs would be useful. When DDAO-SE-labeled T cells were cultured, everolimus reduced rather than enhanced T-cell proliferation, whereas published data claim that rapamycin enhances Treg proliferation (21) . Our data are in line with earlier experiments indicating that Treg conversion was best achieved with antigenically stimulated T cells that exhibited little proliferation (5) . To address this question further in vivo, DDAO-SE-labeled Tregs were adoptively transferred into congenic unmanipulated BALB/c hosts and treated with everolimus daily for a period of 5 d. Reanalysis of transferred Tregs from such mice exhibited no signs of Treg expansion (Fig. 2C) . Similarily, in vitro experiments conducted with ex vivo Treg in the presence of everolimus showed that everolimus interfered with T-cell proliferation of converted Treg (Fig. 2D) .
In the absence of data supporting the notion that everolimus can augment Treg proliferation, we addressed other mechanisms that could account for the increased number of Tregs in vivo in the presence of this drug: Fig. 3 shows that when everolimus is added to cultures in which T cells undergo TGFβ-dependent in vitro conversion, everolimus increased Foxp3 stability, which becomes evident when the converted Treg cells are subsequently cultured in the absence of TGFβ (secondary cultures). The stabilizing effect of everolimus on Foxp3 expression could also be observed, when the drug was added to restimulation cultures of Tregs that had been converted previously in the presence of TGFβ only (Fig. 3 C and D) .
These data could be a result of inhibition of cell cycling by everolimus (Fig. 2) because cell cycling increases the expression of certain methylating enzymes such as DNA methyltransferase 1 (DNMT1), which could interfere with stable Foxp3 expression (13, 22, 23) . Complete demethylation of CpG motifs at the foxp3 locus was shown to correlate with a stable human (24, 25) and mouse Treg phenotype (13) . Pharmacologic inhibition of the DNMT1 activity and knocking down or ablating DNMT1 gene markedly increased the efficacy of induction and stability of Foxp3 expression (13, 22, 23) . Moreover, the absence of DNMT1 in vivo resulted in Foxp3 expression by antigenically stimulated T cells rather than in their immune activation (22) . In our experiments, addition of everolimus to TGFβ-dependent in vitro conversion assays resulted in a significant reduction of DNMT1 expression (Fig. 3 E and F) . This reduction may explain why the use of DNMT1 inhibitors in addition to everolimus did not significantly increase Treg conversion, even though in the absence of everolimus they do so (Fig. 1C) . These results suggest that everolimus works, at least in part, by interfering with DNMT1 expression, which results in increased Treg conversion. The mechanistic interpretation for these findings remains correlative, because demethylating enzymes like DNMT1 act genomwide (13, 22, 23) and there is only a correlation of Foxp3 demethylation and expression.
To address the impact of mTOR inhibition on costimulation during TGFβ-dependent in vitro conversion, we titrated CD28 antibodies. Everolimus could significantly enhance TGFβ-dependent conversion when cells were cultured with CD3 and CD28 antibodies at a 1:1 ratio. The magnitude of the Treg conversion-enhancing effect by inhibitors of the PI3K/Akt/mTOR pathway became even more obvious under conditions of strong costimulation (ratio 1:5), supporting the concept that Foxp3 induction can be increased by enhanced costimulatory signals in the presence of PI3K/Akt/mTOR inhibition (14) , whereas CD28 signals have been shown to interfere with Treg conversion in the presence of TGFβ only. Synergism between TGFβ and mTOR inhibitors has been demonstrated (14, 26) ; however, blockade of the TGFβ signaling pathway did not interfere with Foxp3 induction Fig. 3 . Everolimus increases Foxp3 stability. Naive CD4 + T cells from Foxp3 GFP reporter mice were stimulated with either anti-CD3 or anti-CD3/28 antibodies and subjected to TGFβ-dependent in vitro conversion assays ± everolimus (10 nm). Foxp3 + Tregs from these primary cultures were sorted to high purity and restimulated in the absence of exogenous TGFβ. + Foxp3 + Tregs were sorted to high purity from TGFβ-dependent in vitro conversion assays ± everolimus (primary culture) as described above and restimulated in the absence of TGFβ but ± everolimus (secondary cultures). Foxp3 expression from these secondary Treg cultures was then reassessed on day 4 of restimulation. Bars show percentages of CD4 + CD25 + Foxp3 + Tregs at the end of the secondary culture (C) as well as absolute numbers (D). Data are averages ± SEM and representative of three independent experiments. (E) Naive CD4 + T cells from Foxp3 GFP reporter mice were subjected to TGFβ-dependent in vitro conversion assays (anti-CD3 and anti-CD28 at 5 μg/mL each) ± everolimus as described above. DNMT1 expression was assessed at the end of the conversion process by intracellular staining (E) or by Western blot analysis as shown in F. (F) Cell lysates from cultures as described in E were separated by SDS/PAGE gel with the following conditions: (1) untreated, (2) + TGFβ (0.6 ng/mL), and (3) TGFβ (0.6 ng/mL) + everolimus (10 nM). Representative data of four independent experiments are shown.
enhanced by PI3K/mTOR inhibition, suggesting that different mechanisms are relevant for the observed increase of Treg conversion in the presence of TGFβ or PI3K/mTOR inhibitors. Everolimus interferes with the generation of AP-1 because addition of everolimus to CD4 + T cells subjected to TGFβ-dependent conversion assays in the presence of strong costimulation (anti-CD3 and anti-CD28 at 5 μg/mL each) resulted in a clear reduction of c-jun expression (Fig. 4) . It remains an open question whether AP-1 regulates Foxp3 expression.
Another possible pathway downstream of mTOR may operate through the P2X7 receptor (27, 28) . P2X7 receptors are membrane cation channels gated by extracellular ATP, playing a key role in calcium influx and downstream signaling events associated with the activation and proliferation of T cells. ATP causes the opening to nonselective cation pores (28) . Oxidized ATP (29) functions as a potent and specific inhibitor of the P2X7 receptor and enhances TGFβ-dependent Treg conversion (Fig. 5) .
In T cells from P2X7 receptor knockout mice, the everolimusmediated increase of TGFβ-dependent in vitro conversion is abolished under conditions of weak T-cell stimulation (anti-CD3 only), whereas under conditions of increased costimulation (anti-CD3:CD28 1:1 or 1:5) the everolimus-mediated increase is partly rescued, suggesting that the observed enhancement of Foxp3 expression by PI3K/mTOR inhibition in the presence of stronger costimulatory signals (14) is only partially dependent on P2X7 receptor signaling. Addition of everolimus to naive T cells from WT mice subjected to TGFβ-dependent in vitro conversion assays (anti-CD3 and anti-CD28 at 5 μg/mL each) resulted in a clear reduction of P2X7 receptor protein expression (Fig. 5D) , consistent with the suggestion that everolimus works, at least in part, by controlling several distinct pathways of T-cell activation.
An enhancing effect of mTOR inhibition in vitro was also noted by Cobbold et al. (26) and interpreted to indicate that the PI3K/ Akt/mTOR pathway acts as a nutrient sensor of essential amino acids required for proliferation. Our data establish that the mTOR inhibitor everolimus is a potent enhancer of Treg conversion in vivo. The in vivo results reported in this study are comparable with some more recent studies where limited TCR signaling in conjunction with mTOR inhibition resulted in Treg conversion in vitro (14) and less compatible with another in vitro study where Treg conversion was attempted in the presence of TGFβ (16) . The latter procedure results in Tregs that do not stably express Foxp3, whereas limited TCR signaling in vivo results in stable Foxp3 expression in converted Tregs (14) . Of note, addition of mTOR inhibitors to all of these conversion models resulted in (C) c-jun expression from conversion cultures (anti-CD3 and anti-CD28 at 5 μg/mL each) was assessed by intracellular staining: black histogram (filled), untreated control; gray lined histogram (unfilled), TGFβ (0.3 ng/mL) (solid line) and TGFβ (0.6 ng/mL) (dotted line); light gray histogram (shaded), TGFβ (0.6 ng/mL) + everolimus (10 nM). (D) Cell lysates from the cultures as in C were prepared from the following conditions (1) control; (2) TGFβ at 0.6 ng/mL; and (3) TGFβ (0.6 ng/mL) + everolimus (10 nM), subjected to SDS/PAGE and immunoblotting using c-jun as well as β-actin-specific antibodies. Representative data out of at least five independent experiments are shown. T cells from WT animals were subjected to TGFβ-dependent conversion assays (anti-CD3 and anti-CD28 at 5 μg/mL each) in the presence or absence of everolimus: (1) control, (2) TGFβ at 0.6 ng/mL, (3) TGFβ (0.6 ng/mL) + everolimus (10 nM) and subjected to SDS/PAGE and immunoblotting using P2X7 receptor as well as β-actin-specific antibodies. Representative data out of at least four independent experiments are shown. 
Foxp3
− cells were sorted (from various mice, i.e., injected with antigen alone (where very few such cells could be isolated) and mice injected with everolimus plus IL-2/IL-2 antibody complexes or IL-2/IL-2 anti complexes unify the term IL-2/IL-2ab complexes as seen above alone. In the latter case the increased number of such cells and their restimulation in vitro resulted in some (limited) IL-17 production and some increased IL-10 production (Fig. 6 ). When IL-2/IL-2 complexes IL-2/IL-2ab complexes were given after everolimus treatment the number of CD4 + CD25 +
− cells was also increased but neither IL-17 nor IL-10 production was observed after in vitro restimulation. Thus, everolimus is likewise useful to interfere with secretion of cytokines such as IL-17 when using this particular protocol to expand converted Treg. In terms of proliferation, the CD25 +
− cells were anergic, which could suggest that they might be destined to become regulatory cells rather than immunological effector cells. Thus, at least the conversion protocol combining everolimus and IL-2/IL-2ab complexes does not increase activated effector cells simultaneously with enhancing Treg conversion and expansion (Fig. 6) .
Overall the use of everolimus represents an ideal Treg-vaccination approach, whereas the use of IL-2/IL-2ab complexes yields only a transient increase in Treg numbers. The latter method combined with everolimus to interfere with costimulation may in fact be more useful for treatment rather than prevention of disease. Cancer Institute. Antigen-specific in vivo conversion protocols into Tregs were done as recently described in more detail (32) . Everolimus was from LC Laboratories, doxorubicin was from Sigma, and IL-2/IL-2ab complexes were used following a modification of the protocol initially described in refs. 20, 33.
Cell Sorting and Flow Cytometry. mAbs specific for CD3ε (145-2C11), CD28 (37.51), Thy1.1 (OX-7), Thy1.2 (53-2.1), CD4 (RM4-5), CD25 (PC61), CD44 (IM7), CD62L (MEL-14), Foxp3 (FJK-16s), and IL-17 were from BD, eBioscience or Biolegend, and were used as biotin, FITC, PE, PerCP-Cy5.5, allophycocyanin (APC), or Pacific blue conjugates. Monoclonal antibody to TCR-HA (6.5) was purified and conjugated with Alexa fluor 647 following standard protocols. Fc-receptor blocking monoclonal antibody 2.4G2 was used as culture supernatant. Cell trace far red DDAO-SE reagent was from Molecular Probes (Invitrogen). Where indicated cells were labeled with DDAO-SE at 2 μM by incubation for 4 min at 37°C in PBS plus 0.1% BSA. NT cells were sorted from 6-to 8-wk-old Foxp3 GFP reporter mice as CD4 TGFβ-Dependent in Vitro Conversion Assays. The assays were performed as described in detail elsewhere (32) . For analysis of cytokine production culture supernatants were harvested after 48 h and the concentration of IL-17 and IL-10 were analyzed by a mouse ELISA set (OptEIA, BD). 
